Valuation
- Market cap
- 3,000
- Revenue TTM
- $36,940,000
- Net income TTM
- $-57,190,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -154.82%
- Debt to equity
- -0.03
Trading
- Volume
- 900
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 32,020,000
- Stochastic %K
- —
- Beta
- -0.33
- Analysts
- —
- Price target
- —
Company profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatmen...
Show more
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 353 1 649 2000
- Website
- https://www.nabriva.com
- Address
- Alexandra House, Office 225/227 The Sweepstakes, Dublin, Ireland
Latest news
No headlines yet.
